RxDoctor Payments Data

Vickie Brown

Psychiatric/Mental Health · Cookeville, TNNPI 1295232916

Payments from drug & device makers

$4,220in general payments, 2019–2025

Across 219 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$632
  • Teva Pharmaceuticals USA, Inc.$575
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$542
  • Johnson & Johnson$382
  • Vanda Pharmaceuticals Inc.$321
  • Otsuka America Pharmaceutical, Inc.$281
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,07997%
  • Education$1413%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,220 in reported general payments places this provider in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$18,619
Medicare patients
52
Services billed
207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl94$137,882
Austedo XrDeutetrabenazine15$125,781
Invega SustennaPaliperidone Palmitate17$61,062
RexultiBrexpiprazole19$27,717
TrintellixVortioxetine Hydrobromide17$10,070
Lurasidone Hcl30$7,284
Paliperidone ErPaliperidone25$6,035
Quetiapine Fumarate148$3,557
Buspirone Hcl171$3,451
Lamotrigine188$2,249
Divalproex Sodium ErDivalproex Sodium53$2,155
Oxcarbazepine19$1,789
Atomoxetine Hcl16$1,662
Guanfacine Hcl18$1,596
Aripiprazole52$1,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$632$137,88294 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$575$125,78115 claims
Johnson & JohnsonInvega Sustenna$382$61,06217 claims
Otsuka America Pharmaceutical, Inc.Rexulti$281$27,71719 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$122$10,07017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Cookeville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →